Trials are stopped early for two reasons. Something has gone wrong, or the benefit is large enough that continuing to give half the participants a placebo is no longer defensible.
The kidney trial was stopped for the second reason.
What was measured
Not weight. Not A1c. Hard outcomes: sustained large declines in kidney function, progression to kidney failure requiring dialysis or transplant, and death from kidney or cardiovascular causes.
Those endpoints are what separates a drug that changes a number from a drug that changes what happens to a person.
Stopped early
Halted at interim analysis because benefit was clear
FLOW, NEJM 2024
Hard endpoints
Kidney failure, sustained function loss, cardiovascular and kidney death
T2D + CKD
The population studied — not the general obesity population
Why the mechanism is interesting
The benefit appears larger than weight loss and glucose control alone would predict, which is the same pattern seen in the cardiovascular outcome trials.
Proposed contributors include reduced intraglomerular pressure, direct anti-inflammatory effects on kidney tissue, and improved blood pressure. None of this is settled. What is reasonably established is that the effect does not look like a simple downstream consequence of losing weight.
The practical consequence
Two things follow.
If you have type 2 diabetes, ask whether your kidney function has been checked recently — eGFR and a urine albumin-to-creatinine ratio. Chronic kidney disease is common in diabetes, frequently undiagnosed, and the albumin test in particular is skipped constantly.
If you have both, this is a coverage argument. A kidney indication is not a weight-loss indication, and plans that exclude the latter do not necessarily exclude the former.
The dehydration caveat that should be said out loud
The single realistic way these drugs hurt kidneys is indirect. Severe vomiting or diarrhoea, usually in the days after a dose increase, leading to dehydration, leading to acute kidney injury.
It is avoidable, and the avoidance is unglamorous: deliberate fluid intake on a schedule rather than on thirst, and a low threshold for contacting someone if you cannot keep fluids down for a day.
Knowing where your risky days fall makes that far easier to act on. Vomiting clusters in the seventy-two hours after an escalation for most people, and once you can see that pattern in your own record you can plan fluids around it rather than reacting once you are already behind. Log the dose and the symptom together — Zenday does it in one place — and the window stops being a surprise every time.
The wider point
Almost everyone taking these drugs describes them as weight-loss medication, including many of the people prescribing them.
The outcome trials keep suggesting something broader — cardiovascular events, kidney progression, liver histology, sleep apnea severity. At some point the framing has to catch up, because a drug that prevents dialysis is not usefully described by what it does to a bathroom scale.